MIAMI, April 22, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today provided an update on two abstracts regarding the global Phase 3 somatrogon pediatric trial evaluating somatrogon dosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results